BN Business News
Add your company to Business Communicator →

Business · 27/02/2026Updated: 10/16/2026 · 1 min read

Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases; Correction

Summary

The US Department of Health and Human Services, National Institutes of Health published a correction notice in the Federal Register on February 20, 2025, regarding a patent license for autoimmune disease treatment.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights

Business insights →